Apatini's "ambition is more than" the first line of the Peso Lafferne effect can play.

Wen: Ye Fenghong in October 2014, after 10 years of grinding Apatini shock came out, in the years after the listing of award-winning, its research in the field of liver cancer is twice selected in the United States Oncology Clinical Society General Assembly, not only that, Apatini also with second-line treatment of Class I expert recommendation (Class I evidence) was selected in the 2020 CSCO primary liver cancer diagnosis guide.
, however, Apatini's ambitions do not stop there, and recently the results of Apatini's first-line Pisolaphinie were announced, with the same efficacy that could be played, or would break the pattern of first-line treatment for liver cancer.
the retrospective study, a total of 72 patients with advanced hepatocellular carcinoma were treated with soraphinist or apatinist between January 2016 and December 2017.
were treated with apatini (26 cases, 500 mg per day) or solaffini (46 cases, 400 mg per day, 2 times per day).
result of this is progress-free lifetime (PFS).
secondary endpoints include total survival rate (OS), objective mitigation rate (ORR), disease control rate (DCR), and safety based on improved solid tumor (mRECIST) efficacy evaluation.
results: (Apatini vs Solafini) mPFS: 4.1 vs 3.6 months, 6-month PFS rate 26.4% vs 32.6%, 1-year PFS rate 13.2% vs 17.1% (P-0.925); 5.8% vs 84%, 1-year OS rate 62% vs 64.2% (P-0.811); ORR: 19.2% vs 2.2% (P-0.012), both groups are PR; DCR: 57.7% vs 50% (P-0.53).
, it can be seen that in patients with advanced hepatocellular carcinoma, apatinist is comparable to PFS and OS of Solafini, but the objective response rate is better.
because this study is retrospective, further forward-looking randomized studies are needed to confirm the benefits of apatini.
to the difficulties, Apatini's achievements in the field of advanced hepatocellular carcinoma In 2014, Apatini's prospective, national multi-center, randomized, open, dose-exploratory Phase II trials for advanced liver cancer were selected in asCO Wall, results showed 850 mg/qd or 7 The disease control rate (DCR) of 50 mg/qd apatini is 48.57 percent and 37.25 percent, respectively, and the medium lifetime (mOS) is 9.7 months and 9.8 months, respectively, suggesting potential survival benefits in patients with advanced liver cancer.
In 2020, the "Random, Double-Blind, Placebo-Controlled Phase III AHELP Study of Apatinib's Second-Line Treatment of Advanced Hepatocellular Carcinoma (HCC)," led by Professor Qin Shuxuan and jointly conducted by 31 cancer centers nationwide, was received by the ASCO General Assembly and selected as an oral report.
results showed that apatinib significantly extended the mesoOS (8.7 months to 6.8 months) of chinese advanced HCC patients who had previously been treated compared to placebo.
, the mid-level progress-free lifetime (PFS) in the Apatini group was 4.5 months, higher than the 1.9 months in the control group.
, the objective mitigation rate (ORR) in the Apatini group was 10.7%, significantly higher than the 1.5% in the control group.
in terms of safety, treatment-related adverse events are similar to those approved for the treatment of advanced stomach cancer, no new adverse events have been observed, and patients have better tolerance.
based on the encouraging results of the AHELP study, in the second-line treatment section of the late HCC, the new guidelines formally include apardinium as a second-line treatment recommendation, with a recommended level of I.grade and an evidence level of 1A.
It is our country's researchers after many years of hard work, so that Apatini in the field of liver cancer to promote the update of the high-level evidence-based medical evidence, liver cancer second-line treatment has become a new standard, for the vast number of liver cancer patients in China to provide their own treatment plan.
, however, Apatini is not content with it.
has not stopped exploring the field of liver cancer since it was approved, and is currently experimenting with innovative combination therapies.
For example, a joint radiotherapy study confirmed that apatinists can enhance radiation effects by inhibiting PI3K/AKT signaling pathlines in hepatocellular carcinoma; It has been proved that Apatini inhibits angiogenesis and growth of liver cancer by lowering PI3K-Akt, RAF-MEK-ERK and P38-MAPK, and that iodine oil containing apatini is an effective treatment for hepatocellular carcinoma.
the future, Apatini is bound to bring more possibilities.
Apatini is the world's first small molecule anti-angiogenesic target drug to be proven safe and effective in the treatment of advanced stomach cancer, and its main mechanism of action is competitive binding to the attainment point of tyrosine in the subject cell, highly selective inhibits VEGFR-2 tyrosine kinase activity, blocks signal conduction after the binding of endodermal growth factor (VEGF), and thus inhibits tumor angiogenesic. in the seven years since
's listing, Apatini has been exploring and showing good therapeutic activity in the field of liver cancer, especially single-drug or combined TACE and immunotherapy, which has added new treatment options to the comprehensive treatment of liver cancer in China.
with the gradual development of follow-up studies and the accumulation of more clinical experience, it is believed that more cancer patients will benefit from the application of apatini.
source: 1. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study; 2.2014 American Cancer Annual Meeting (ASCO), Abstract No: 4019; 3. J Exp Clin Cancer Res. 2019;38 (1):454.4.Sci Rep. 2020 Feb 19;10 (1):2964.